Key Findings:  The authors posit that blockers of CB1 may represent a novel therapeutic agents in the treatment of CKD.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  France
Year of Pub:  2021
Cannabinoids Studied:  Endocannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1